Orchestra BioMed (NASDAQ:OBIO - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.
Orchestra BioMed Price Performance
NASDAQ:OBIO traded up $0.16 during trading hours on Friday, reaching $4.51. 99,841 shares of the company traded hands, compared to its average volume of 82,405. Orchestra BioMed has a 1-year low of $3.75 and a 1-year high of $8.87. The stock has a market cap of $171.44 million, a P/E ratio of -2.80 and a beta of 0.59. The firm's 50-day moving average is $4.99 and its 200-day moving average is $5.22.
Institutional Investors Weigh In On Orchestra BioMed
An institutional investor recently raised its position in Orchestra BioMed stock. Bank of America Corp DE grew its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) by 42.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,780 shares of the company's stock after buying an additional 7,036 shares during the quarter. Bank of America Corp DE owned 0.06% of Orchestra BioMed worth $95,000 at the end of the most recent quarter. Institutional investors own 53.55% of the company's stock.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of Orchestra BioMed in a research note on Monday, March 10th. Barclays started coverage on shares of Orchestra BioMed in a research report on Thursday, January 2nd. They issued an "overweight" rating and a $16.00 price objective for the company. Finally, BTIG Research initiated coverage on shares of Orchestra BioMed in a research report on Thursday. They set a "buy" rating and a $12.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $15.40.
Check Out Our Latest Stock Analysis on OBIO
Orchestra BioMed Company Profile
(
Get Free Report)
Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Featured Articles
Before you consider Orchestra BioMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.
While Orchestra BioMed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
